Flow-FISH evaluation of telomere length in philadelphia-negative myeloproliferative neoplasms

Haematologica

Volumn 96, Issue 8, 2011, Pages 1236-1238

  Elena, Chiara ^a   Rumi, Elisa ^a   Portolan, Monica ^a   Porta, Matteo G ^a   Pascutto, Cristiana ^a   Passamonti, Francesco ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

JAK2; Myeloproliferative neoplasm; Telomere

Indexed keywords

HYDROXYUREA; JANUS KINASE 2; PHENYLALANINE; VALINE;

ADULT; AGED; BLOOD CELL COUNT; CLINICAL EXAMINATION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GRANULOCYTE; HUMAN; ITALY; LETTER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYCYTHEMIA VERA; TELOMERE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; TELOMERE; TELOMERE HOMEOSTASIS; YOUNG ADULT;

EID: 79961044558     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047803     Document Type: Letter

References (12)

1. Calado RT, Young NS. Telomere diseases. N Engl J Med. 2009;361(24):2353-65.
2. Ferraris AM, Pujic N, Mangerini R, Rapezzi D, Gallamini A, Racchi O, et al. Clonal granulocytes in polycythaemia vera and essential thrombocythaemia have shortened telomeres. Br J Haematol. 2005;130(3):391-3.
3. Terasaki Y, Okumura H, Ohtake S, Nakao S. Accelerated telomere length shortening in granulocytes: a diagnostic marker for myeloproliferative diseases. Exp Hematol. 2002;30(12):1399-404.
4. Spanoudakis E, Bazdiara I, Pantelidou D, Kotsianidis I, Papadopoulos V, Margaritis D, et al. Dynamics of telomere's length and telomerase activity in Philadelphia chromosome negative myeloproliferative neoplasms. Leuk Res. 2011;35(4):459-64.
5. Bernard L, Belisle C, Mollica L, Provost S, Roy DC, Gilliland DG, et al. Telomere length is severely and similarly reduced in JAK2V617F-positive and-negative myeloproliferative neoplasms. Leukemia. 2009;23(2):287-91.
6. Ruella M, Salmoiraghi S, Risso A, Carobbio A, Sivera P, Ricca I, et al. Telomere length in Ph-negative chronic myeloproliferative neoplasms: it is reduced according to JAK2 V617F mutation allele burden and it is not affected by cytoreductive treatment with hydroxyurea. ASH Annual Meeting Abstracts 2010;116:1975.
7. Rufer N, Brummendorf TH, Kolvraa S, Bischoff C, Christensen K, Wadsworth L, et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med. 1999;190(2):157-67.
8. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-82.
9. Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24(9):1574-9.
10. Pietra D, Brisci A, Rumi E, Boggi S, Elena C, Pietrelli A, et al. Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica. 2011;96(4):607-11.
11. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon 2a. Blood. 2006;108(6):2037-40.
12. Pardanani A, Vannucchi AM, Passamonti F, Cervantes F, Barbui T, Tefferi A. JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations. Leukemia. 2011;25(2):218-25.